[HTML][HTML] COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

S Beyerstedt, EB Casaro, ÉB Rangel - European journal of clinical …, 2021 - Springer
COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. Angiotensin-
converting enzyme 2 (ACE2) is not only an enzyme but also a functional receptor on cell …

[HTML][HTML] COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

M Nishiga, DW Wang, Y Han, DB Lewis… - Nature Reviews …, 2020 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …

[HTML][HTML] Extrapulmonary manifestations of COVID-19

A Gupta, MV Madhavan, K Sehgal, N Nair… - Nature medicine, 2020 - nature.com
Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …

COVID-19 and cardiovascular disease

KJ Clerkin, JA Fried, J Raikhelkar, G Sayer, JM Griffin… - Circulation, 2020 - Am Heart Assoc
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and> 3
000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute …

Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19

HR Reynolds, S Adhikari, C Pulgarin… - … England Journal of …, 2020 - Mass Medical Soc
Background There is concern about the potential of an increased risk related to medications
that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus …

[HTML][HTML] Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs …

AA Rabaan, SH Al-Ahmed, J Muhammad, A Khan… - Vaccines, 2021 - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious …

Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19

M Vaduganathan, O Vardeny, T Michel… - … England Journal of …, 2020 - Mass Medical Soc
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone
system blockers on angiotensin-converting enzyme 2 levels and activity in humans are …

[HTML][HTML] Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open …

JB Cohen, TC Hanff, P William, N Sweitzer… - The lancet respiratory …, 2021 - thelancet.com
Background Biological considerations suggest that renin–angiotensin system inhibitors
might influence the severity of COVID-19. We aimed to evaluate whether continuing versus …

[HTML][HTML] Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

S Shibata, H Arima, K Asayama, S Hoshide… - Hypertension …, 2020 - nature.com
Abstract Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people …

Coronavirus disease 2019 (COVID‐19): do angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?

R Sommerstein, MM Kochen, FH Messerli… - Journal of the …, 2020 - Am Heart Assoc
China, in December 2019. 1 As of March 20, 2020, 244 602 patients have tested positive
worldwide; and 10 031 (4.1%) of these patients were reported to be deceased because of …